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Objectives: To investigate the remaining life expectancy with and without polypharmacy for Swedish
women and men aged 65 years and older.
Design: Age-speciﬁc prevalence of polypharmacy from the nationwide Swedish Prescribed Drug Register
(SPDR) combined with life tables from Statistics Sweden was used to calculate the survival function and
remaining life expectancy with and without polypharmacy according to the Sullivan method.
Setting: Nationwide register-based study.
Participants: A total of 1,347,564 individuals aged 65 years and older who had been prescribed and
dispensed a drug from July 1 to September 30, 2008.
Measurements: Polypharmacy was deﬁned as the concurrent use of 5 or more drugs.
Results: At age 65 years, approximately 8 years of the 20 remaining years of life (41%) can be expected to
be lived with polypharmacy. More than half of the remaining life expectancy will be spent with poly-
pharmacy after the age of 75 years. Women had a longer life expectancy, but also lived more years with
polypharmacy than men.
Discussion: Older women and men spend a considerable proportion of their lives with polypharmacy.
Conclusion: Given the negative health outcomes associated with polypharmacy, efforts should be made to
reduce the number of years older adults spend with polypharmacy to minimize the risk of unwanted
consequences.
 2016 AMDA e The Society for Post-Acute and Long-Term Care Medicine. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Polypharmacy is common among older adults and has been linked
to an increased risk of drug-drug interactions, inappropriate pre-
scribing, adverse drug reactions, lower adherence to drug regimens,
hospitalization, and even mortality.1e5 Polypharmacy can be deﬁned
as the concurrent use of multiple medications1 (often with the cutoff
of 5 or more drugs; a cutpoint that has been shown to have good
discriminative properties6). The prevalence of polypharmacy is often
found to increase with age.7 This can be problematic given that theh Council (grant 2012e1503)
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and Long-Term Care Medicine. Thaltered pharmacokinetics and pharmacodynamics in old age, together
with increasing number of comorbidities, make older people more
sensitive to the effects of drugs.8
Older adults have been found to use an increasing number of drugs
as they age,7 and longitudinal studies show an increasing proportion
of persons with polypharmacy over time.9 Earlier studies have high-
lighted the importance of considering life expectancy in relation to
prescribing, especially for patients with limited life expectancy.5,10 In
persons with limited life expectancy, the time needed to have the
potential beneﬁts of a treatment will in some cases be longer than
their expected remaining life. However, little is known about how long
time older adults spend with polypharmacy.
To our knowledge, this is the ﬁrst study to quantify the estimated
time older people are exposed to polypharmacy. By combining in-
formation on length of life and information on polypharmacy by age
and sex, we can estimate the time spent with polypharmacy in older
women and men in Sweden in relation to life expectancy. Thus, theis is an open access article under the CC BY-NC-ND license (http://creativecommons.
J.W. Wastesson et al. / JAMDA 17 (2016) 31e3532aim of the study was to investigate the proportion of remaining life,
and number of years, spent with polypharmacy after age 65 years
among Swedish women and men.
Methods
Data Source
The Swedish Prescribed Drug Register (SPDR) was used to measure
the prevalence of polypharmacy in the Swedish population aged
65 years and older. The SPDR contains individual-level information on
all drugs prescribed and ﬁlled at pharmacies by Swedish citizens
(including prescribed vitamins, minerals, dermatological and eye
preparations, and as-needed used drugs), but not over-the-counter
drugs and drugs used in hospitals.11
Sample
Among persons aged 80 years and older, approximately 90% of the
total population is covered by the SPDR,12 the coverage in the younger
age groups was lower, approximately 80%. Persons that were not
covered by the SPDR have not dispensed a drug during the study
period. For each individual alive at the end of the study period, we had
information on all prescription drugs dispensed from July 1 to
September 30, 2008 (n ¼ 1,347,564).
Drug Use and Polypharmacy
The dispensed drugs were classiﬁed according to the Anatomical
Therapeutic and Chemical (ATC) classiﬁcation system. If a person was
prescribed 2 drugs with the same ATC code (5th level, chemical sub-
stance) during the study period, it was counted as one dispensing. By
combining the information on date of dispensing, the amount of drug
and dosage, we could calculate the number of drugs that should be
used on September 30, 2008 (for a more detailed description of the
calculations, see Wastesson et al12). Polypharmacy was deﬁned as the
concurrent use of 5 or more drugs, calculated as a 1-day-point prev-
alence, for September 30, 2008.
Statistical Analysis
The Sullivan method13 is usually used for dividing life expectancy
into disabled and disability-free years of life. We propose a novel use
of the Sullivan method to calculate the survival function and the
remaining years of life spent with and without polypharmacy at
different ages. Information on period life tables for 2008 were avail-
able from Statistics Sweden.14 Mortality data were available by single
age groups for ages 65 to 99 years, and with an open-ended age in-
terval for centenarians (100þ years). The calculations were done for
the total population aged 65 years and older, and given the gender
differences in drug use,15 for women and men separately. A more
detailed description on the calculations used in the Sullivan method
can be found elsewhere.16 The study was approved by the ethical
board in Stockholm (Dnr 2009/477e31/3).
Results
A total of 1,347,564 individuals (775,109 women; 572,455 men)
aged 65 years or older had a record in the SPDR. The use of drugs
ranged from 0 to 40 drugs concomitantly, with a median of 4 drugs
(interquartile range 2e6). The survival function for Swedish women
and men, partitioned into survivors with and without polypharmacy
(5 drugs) are depicted in Figure 1.
The overall survival for female and male Swedes after age 65 years
is represented by the outer contour line in Figure 1 (A and B). Thehigher longevity of women as opposed to men can be perceived in
women’s more rectangular survival function; with half of the women
surviving to the age of 87 years compared with 84 years for men. The
shaded area under the curve separates the number of survivors into
those with and without polypharmacy at each age. Women have a
larger shaded area, indicating a larger proportion of women with
polypharmacy at each age.
The frequency of polypharmacy increased with age, from 27% at
age 65 years to approximately 60% among nonagenarians (Table 1).
However, in the centenarian group (100þ), the frequency of poly-
pharmacy was lower (52%) than among nonagenarians (59%). Women
and men had a similar frequency of polypharmacy until age 80 years,
but women had a higher prevalence of polypharmacy between ages
80 and 99 years. The gender difference declined in the centenarian
group.
In Table 1, the polypharmacy-free life expectancies for the total
population and for women and men are shown. In the total study
population, the remaining years of life were 20 at age 65 years,
10 years at age 78, and 5 years at age 87. At age 65 years, approxi-
mately 8 of the 20 remaining years of life could be expected to be lived
with polypharmacy (41.2%). After the age of 75 years, more than half of
the remaining life expectancy was spent with polypharmacy.
Women had a longer life expectancy than men until advanced
ages. Women also tended to live more years, and have a larger share of
life with polypharmacy, than men. Women could expect to spend 50%
or more of their remaining life with polypharmacy after age 73 years,
whereas men could expect to spend 50% or more with polypharmacy
at age 79 years (Figure 2).
Discussion
This is the ﬁrst study to investigate polypharmacy-free life ex-
pectancy. A 65-year-old in Sweden can expect to live 20more years. Of
these, 8 years will be spent with polypharmacy. Women have a longer
life expectancy than men, but can expect to live half of the remaining
life with polypharmacy after the age of 73 years compared with
79 years for men. Thus, women live more years, and a larger share of
their remaining life, with polypharmacy than men. Polypharmacy is
not necessarily inappropriate, but given the risk of drug-drug in-
teractions, inappropriate prescribing, adverse drug reactions, lower
adherence to drug regimens, hospitalization, and mortality,1,2 it
should be avoided if possible. Our results suggest that a large pro-
portion of older adults will spend many years exposed to poly-
pharmacy. Based on our calculations, more than two-ﬁfths of the
remaining lifewas expected to be livedwith polypharmacy for Swedes
aged 65 years in 2008 if theywere to follow the regimen ofmedication
and mortality observed in 2008.
The use of drugs in general, as well as the use of multiple medi-
cations, is increasing year-by-year in the older population.7,17,18 Older
adults with comorbidities are rarely included in drug trials.19,20 Thus,
the use of drugs among older adults can to a large extent be consid-
ered experimental. The increased use of drugs is partly driven by the
use of single disease guidelines,21 and it has been suggested that drug
treatment in complex older adults should focusmore on the deliberate
avoidance of polypharmacy.10 Conceptual frameworks have been
developed to include deprescribing in the prescribing process.22 In
fact, there is emerging evidence that deprescribing can have positive
health effects for older adults with complex health problems.23,24
Thus, our ﬁnding that older adults spend extensive periods with
polypharmacy should be a case of concern.
Especially among older adults with a very limited life expectancy,
where the time needed before a treatment will have a potentially
beneﬁcial effect can be longer than their remaining life expectancy,
deprescribing could be warranted.5,10 However, we ﬁnd that people
can expect to spend more than half of their remaining life expectancy
Fig. 1. Survival function separated by polypharmacy (with and without), Swedish female (A) and male (B) population 2008.
J.W. Wastesson et al. / JAMDA 17 (2016) 31e35 33exposed to polypharmacy all theway up to 100 years of age. Given that
a centenarian on average can expect to live only 1 more year, their
limited life expectancy should be taken into account when clinical
decisions are made. In line with this, we found that centenarians
actually had a lower prevalence of polypharmacy than nonagenarians.
The prevalence of polypharmacy in our study increased from
approximately 30% at age 65 years, to approximately 65% at age
95 years. The prevalence of polypharmacy has been found to range
between 27% and 59% in a systematic review of nonhospitalized older
adults living at home,25 and between 38% and 91%, in a review of older
adults in long-term care facilities.26 Our results are in line with therange presented in the reviews, given that we both include home-
dwelling and persons living in long-term care facilities. Ideally, our
results should have been presented for persons living at home and
long-term care facilities separately. But data on life expectancy in
long-term care facilities are not available in Sweden.
Women have a longer life expectancy, but also experience more
health problems than men; the so called male-female health para-
dox.27e30 We found that women have longer life expectancy, and
spend a larger proportion and more years, with polypharmacy. Thus,
women spend more time exposed to the risks of polypharmacy both
in absolute years and as a proportion of their life. The similarity in
Table 1
Prevalence of Polypharmacy (PP) and Life Expectancy (LE) for Selected Ages Above 65 Total LE and divided into years with and without polypharmacy of the total remaining LE.
Swedish total, female and male population 2008.
Age Total Population Female Population Male Population
Polypharmacy,
%
LE, y Polypharmacy,
%
LE, y Polypharmacy,
%
LE, y
Total Without PP With PP Total Without PP With PP Total Without PP With PP
65 26.6 19.7 11.6 8.1 26.2 21.0 12.1 8.9 27.0 18.1 11.0 7.1
70 32.8 15.7 8.6 7.1 32.6 16.9 9.0 7.9 33.0 14.3 8.1 6.2
75 40.1 12.0 6.1 6.0 40.8 13.0 6.3 6.6 39.4 10.8 5.8 5.1
80 47.3 8.7 4.1 4.7 48.4 9.4 4.2 5.2 45.8 7.7 3.9 3.9
85 53.9 6.0 2.6 3.4 55.4 6.4 2.6 3.8 51.3 5.3 2.5 2.8
90 58.9 3.9 1.6 2.3 60.9 4.1 1.6 2.5 54.6 3.5 1.6 1.9
95 60.7 2.5 1.0 1.5 62.2 2.6 1.0 1.6 55.9 2.4 1.1 1.3
100þ 52.4 1.1 0.5 0.6 48.1 0.7 0.4 0.4 48.1 2.4 1.2 1.1
J.W. Wastesson et al. / JAMDA 17 (2016) 31e3534results between drug use and health are expected because drug use is
considered as a valid proximate measure of health status.31,32 Hence,
polypharmacy-free life expectancy could potentially be used to study
health differentials between groups.0
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Fig. 2. Life expectancy, total, with and without polypharmaThe present study has some limitations. By using the Sullivan
method, we assume that people with polypharmacy (based on our
1-day-point prevalence) stay on polypharmacy. The validity of this
assumption should ideally be studied within a longitudinal95 100+
Total life expectancy
Polypharmacy-free life
expectancy
Life expectancy with
polypharmacy
95 100+
Total life expectancy
Polypharmacy-free life
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cy. Swedish female (A) and male (B) population, 2008.
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people transitioning out of polypharmacy should not pose a major
limitation to this study. However, it might be problematic in the
centenarian group where the prevalence of polypharmacy was lower
than in the younger age groups. The low use of drugs among cente-
narians12,33,34 could reﬂect a transition out of polypharmacy as an
end-of-life approach when discontinuation of drug therapy is war-
ranted.33 Further, we do not have information about over-the-counter
drugs, which leads to an underestimation of the total consumption of
drugs. A more general limitation with the Sullivan method is that it
assumes the same mortality pattern in both the group with and
without polypharmacy. Because drug use also can be used as a health
measure, the group with polypharmacy will probably have higher
mortality. The strengths of this study are the complete drug use data
available from Swedish registers, and the method used for calculating
the 1-day-point prevalence of drug use. The 1-day-point prevalence is
conservative comparedwith other studies that have summarized drug
use from a longer time period. If the persons are adherent to their drug
regimens, all the prescribed drugs should have been consumed
concomitantly on the day of the study.
Conclusion
This study highlights the extensive proportion of their remaining
lives older adults spend exposed to polypharmacy. On average, a
65-year-old Swede will spend 8 years of his or her remaining 20 years
of life with polypharmacy. Given the negative health outcomes asso-
ciated with polypharmacy, efforts should be made to reduce the
number of years older adults spend with polypharmacy to minimize
the risk of unwanted consequences. The remaining life expectancy of
the patient should be taken into consideration when managing the
drug treatment of older patients.
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